About us

COMPANY

Company History

2018

  • Mar. Established a branch office in Singapore (Spectrum incubating, Golden Equator)
  • Apr. Launched in Taiwan (Tseng Hsiang Life Science Ltd.)
    Attracted investment from Korea Credit Guarantee Fund (Series A)
  • Jun. Launched in Germany (PELOBIOTECH GmbH)
    Launched in Singapore (Afirmus Biosource Pte. Ltd.)
    Expanded the GMP-grade plant
  • Sep. Selected for the small and medium enterprise technical innovation development project by the Ministry of SMEs and Startups
  • Nov. Participated in the 2018 Qingdao Korea–China Technology Transfer Convention (Qingdao, China)

2017

  • Feb. Established a GMP-grade manufacturing plant
  • Apr. Launched in Japan (Primetech)

2016

  • Feb. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, China)
  • May. Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells (patent registered, Korea)
  • Jul. Attracted investment from Young Science Co., Ltd.
  • Dec. Won the prime minister’s citation

2015

  • Mar. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, Japan)
  • Jun. Selected for the technology commercialization task by the Korea Institute of Marine Science & Technology Promotion
  • Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (patent registered, Japan)
    Selected for the technology transfer and development project by Korea Technology & Information Promotion Agency for SMEs

2014

  • Mar. Launched the qPCR product
  • Aug. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (2 patents registered, USA)
  • Oct. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, USA)

2013

  • Jun. Launched DNA-free Taq DNA polymerase
  • Aug. “Method for eliminating mycoplasma contamination of cells” (Patent registered, Korea)
  • Oct. Selected for the start-up and growth tasks for the small and medium enterprises

2012

  • Jan. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, Korea)
  • Apr. Acknowledged company-affiliated research institute (Korea Industrial Technology Association)
  • Aug. Launched a diagnosis kit for the Mycoplasma qPCR
  • Sep. Selected for a venture capital investment-related mentoring business

2011

  • Feb. Registered a BioMycoX trademark
  • Apr. “Bone-transplant or a bone-filing composition comprising a dihydroxybenzoic acid derivative” (Patent pending, Europe)
  • Aug. Launched the mycoplasma-related products in the United States
  • Sep. Selected for the future marine industry technology development project in 2011 (support for marine small and medium venture businesses)

2010

  • Feb. Certified as a venture company (Korea Technology Finance Corporation)
  • Mar. Selected as a G-startup project company in Gyeonggi Province
  • Apr. Selected for a prestart-up support task in Gyeonggi Province
  • Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (Patent registered, Korea)

2009

  • Oct. Selected for residence in the business incubation center of Ajou University and started the business
Now ~ 2016

2018

  • Mar. Established a branch office in Singapore (Spectrum incubating, Golden Equator)
  • Apr. Launched in Taiwan (Tseng Hsiang Life Science Ltd.)
    Attracted investment from Korea Credit Guarantee Fund (Series A)
  • Jun. Launched in Germany (PELOBIOTECH GmbH)
    Launched in Singapore (Afirmus Biosource Pte. Ltd.)
    Expanded the GMP-grade plant
  • Sep. Selected for the small and medium enterprise technical innovation development project by the Ministry of SMEs and Startups
  • Nov. Participated in the 2018 Qingdao Korea–China Technology Transfer Convention (Qingdao, China)

2017

  • Feb. Established a GMP-grade manufacturing plant
  • Apr. Launched in Japan (Primetech)

2016

  • Feb. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, China)
  • May. Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells (patent registered, Korea)
  • Jul. Attracted investment from Young Science Co., Ltd.
  • Dec. Won the prime minister’s citation
2015 ~ 2011

2015

  • Mar. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, Japan)
  • Jun. Selected for the technology commercialization task by the Korea Institute of Marine Science & Technology Promotion
  • Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (patent registered, Japan)
    Selected for the technology transfer and development project by Korea Technology & Information Promotion Agency for SMEs

2014

  • Mar. Launched the qPCR product
  • Aug. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (2 patents registered, USA)
  • Oct. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, USA)

2013

  • Jun. Launched DNA-free Taq DNA polymerase
  • Aug. “Method for eliminating mycoplasma contamination of cells” (Patent registered, Korea)
  • Oct. Selected for the start-up and growth tasks for the small and medium enterprises

2012

  • Jan. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, Korea)
  • Apr. Acknowledged company-affiliated research institute (Korea Industrial Technology Association)
  • Aug. Launched a diagnosis kit for the Mycoplasma qPCR
  • Sep. Selected for a venture capital investment-related mentoring business

2011

  • Feb. Registered a BioMycoX trademark
  • Apr. “Bone-transplant or a bone-filing composition comprising a dihydroxybenzoic acid derivative” (Patent pending, Europe)
  • Aug. Launched the mycoplasma-related products in the United States
  • Sep. Selected for the future marine industry technology development project in 2011 (support for marine small and medium venture businesses)
2010 ~ 2009

2010

  • Feb. Certified as a venture company (Korea Technology Finance Corporation)
  • Mar. Selected as a G-startup project company in Gyeonggi Province
  • Apr. Selected for a prestart-up support task in Gyeonggi Province
  • Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (Patent registered, Korea)

2009

  • Oct. Selected for residence in the business incubation center of Ajou University and started the business
Menu